Related compounds
Mobile phase
Proceed as directed in the Assay.
Standard solution
Dissolve an accurately weighed quantity of
USP Bicalutamide RS in a minimum amount of tetrahydrofuran, and dilute quantitatively with
Mobile phase to obtain a solution having a known concentration of about 0.02 mg per mL.
System suitability solution
Dissolve an accurately weighed quantity of
USP Bicalutamide RS and
USP Bicalutamide Related Compound B RS in a minimum amount of tetrahydrofuran, and dilute quantitatively with
Mobile phase to obtain a solution having known concentrations of about 0.05 mg per mL of bicalutamide and 0.02 mg per mL of bicalutamide related compound B, respectively.
Test solution
Dissolve an accurately weighed quantity of Bicalutamide in a minimum amount of tetrahydrofuran, and dilute quantitatively with Mobile phase to obtain a solution having a known concentration of about 4.0 mg per mL.
Chromatographic system (see Chromatography
621
)
Prepare as directed in the
Assay. Chromatograph the
System suitability solution, and record the peak responses as directed for
Procedure: the resolution,
R, between bicalutamide and bicalutamide related compound B is not less than 2.0; the tailing factor for the bicalutamide peak is less than 1.3; and the relative standard deviation of the bicalutamide peak for replicate injections is not more than 4%.
Procedure
Separately inject equal volumes (about 10 µL) of the
Standard solution and the
Test solution into the chromatograph, and record the chromatograms. Calculate the percentage of each impurity in the portion of Bicalutamide taken by the formula:
100(CS / CU)(ri / rS)
in which
CS and
CU are the concentrations, in mg per mL, of bicalutamide in the
Standard solution and the
Test solution, respectively;
ri is the peak response for each impurity obtained from the
Test solution; and
rS is the peak response for bicalutamide obtained from the
Standard solution. The limits are given in
Table 1.
Table 1
Name |
RRT |
Limit (%) |
Des-fluoro analog1 |
0.74 |
0.2 |
2-Fluoro isomer2 |
0.78 |
0.2 |
Des hydroxy analog3 |
1.19 |
0.2 |
Individual unspecified impurity |
|
0.1 |
Total unspecified impurities |
|
0.3 |
Total impurities |
|
0.5 |
1
(RS)-4¢-Cyano-3-phenylsulfonyl-2-hydroxy-2-methyl-3¢-(trifluoromethyl)propionanilide.
|
2
(RS)-4¢-Cyano-3-(2-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3¢-(trifluoromethyl)-propionanilide.
|
3
(RS)-4¢-Cyano-3-(4-fluorophenylsulfonyl)-2-methyl-3¢-(trifluoromethyl)propionanilide.
|
Assay
Mobile phase
Prepare a mixture of water, methanol, and tetrahydrofuran (55:30:15).
Standard preparation
Dissolve an accurately weighed quantity of
USP Bicalutamide RS in a minimum amount of tetrahydrofuran, and dilute quantitatively with
Mobile phase to obtain a solution having a known concentration of about 0.05 mg per mL.
Assay preparation
Dissolve an accurately weighed quantity of Bicalutamide in a minimum amount of tetrahydrofuran, and dilute quantitatively with Mobile phase to obtain a solution having a known concentration of about 0.05 mg per mL.
Chromatographic system (see Chromatography
621
)
The liquid chromatograph is equipped with a 270-nm detector and a 5-mm × 25-cm column that contains 5-µm packing L1. The flow rate is about 1.8 mL per minute. The column temperature is maintained at 35

to 40

. Chromatograph the
Standard preparation, and record the peak responses as directed for
Procedure: the relative standard deviation for replicate injections is not more than 2%.
Procedure
Separately inject equal volumes (about 10 µL) of the
Standard preparation and the
Assay preparation into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity, in percent, of C
18H
14F
4N
2O
4S in the portion of Bicalutamide taken by the formula:
100(CS / CU)(rU / rS)
in which
CS is the concentration, in mg per mL, of
USP Bicalutamide RS in the
Standard preparation; CU is the concentration of Bicalutamide, in mg per mL, in the
Assay preparation; and
rU and
rS are the peak responses obtained from the
Assay preparation and the
Standard preparation, respectively.